Growth Hormone Deficiency Clinical Trial
Official title:
Gender-Specific Effects of Physiologic GH Administration on Cardiovascular Risk Factors in Women With Growth Hormone Deficiency
The purpose of the study is to evaluate the effects of growth hormone replacement on women
with growth hormone deficiency. Growth hormone deficiency means the body no longer produces
growth hormone due to a tumor or some kind of disease of the brain in an area called the
pituitary/hypothalamic region. This is the area of the brain where growth hormone is
normally produced. We, the researchers at Massachusetts General Hospital, will establish the
effects of growth hormone replacement on cardiovascular parameters (laboratory tests, the
flexibility of the arteries, changes in heart rate) in women with growth hormone deficiency.
Our goal is to see if this therapy:
- has effects on women's cardiovascular risk markers (special blood tests which indicate
how healthy the heart and arteries are)
- has effects on women's types and levels of various substances circulating in their
blood
- in women affects the stiffness of their arteries and heart rate variability in parallel
with changes in cardiovascular risk markers
- has different effects depending on whether women are pre or post menopausal.
Participation in this study is expected to last approximately 12 months.
The aim of the study is to evaluate the gender specific effects of physiologic Growth
Hormone (GH) replacement in women with GH deficiency on the basis of pituitary/hypothalamic
region tumors, radiation, or surgery on cardiovascular risk markers and arterial
distensibility. Cardiovascular mortality in growth hormone (GH) deficient adults has been
shown to be increased in a number of retrospective studies. Increased arterial intima-media
thickness, increased prevalence of atherosclerotic plaques and endothelial dysfunction have
been reported in growth hormone deficient adults both in childhood and adulthood onset
forms.
The growth hormone deficiency (GHD) syndrome is associated with a cluster of
cardiovascular-risk factors such as central adiposity, increased visceral fat, insulin
resistance, dyslipoproteinemia and decreased plasma fibrinolytic activity. GH administration
has effects on a number of these factors, but it is unknown which mechanisms are implicated
in GH action on the process of atherosclerosis. In addition to alterations in
atherosclerotic markers, abnormalities in cardiac function and structure have been reported
among patients with GHD possibly contributing to the increased cardiovascular mortality. In
addition, GHD is associated with cardiac autonomic dysfunction that may also contribute to
cardiovascular mortality and improves with GH replacement therapy.
The vast majority of studies have focused primarily on men and the gender-specific effects
of GH replacement on cardiovascular risk factors remain unknown. In addition to being of
interest in terms of understanding the physiologic effects of GH therapy, there are
important therapeutic implications regarding data in women. Cardiovascular disease is the
leading cause of mortality in women. Effects of GH replacement on bone density may be less
pronounced in women and because specific GH effects on cardiovascular risk factors in women
are unknown, many adult women with GHD are untreated.
Long-term GH treatment decreases total body fat including visceral fat. Decreases in central
fat as assessed by waist to hip ratio have been reported in some studies, but not in others.
Administration of GH causes insulin resistance acutely but long-term therapy may restore
glucose sensitivity. GH treatment increases lipoprotein (a) (Lp (a)) levels but its effects
on other lipoproteins are still controversial. Some studies have reported decreases in LDL
cholesterol with or without increases in HDL cholesterol with GH administration, while
others have not. Twelve months of GH replacement improves left ventricular mass and cardiac
performance in young adults with GHD. Key factors likely involved in the discrepant findings
include heterogeneity of patients studied in terms of age of onset of the GH deficiency
(childhood versus adulthood), gender, severity of GHD and methodologic issues such as dose
and duration of GH administration. In addition, many of the studies have no control period.
Inflammation plays a central role in the pathophysiology of atherosclerosis. Each
atherosclerotic lesion represents a different stage of a chronic inflammatory process in the
arterial wall and different markers along the inflammatory cascade have been reported to
predict cardiovascular risk [34]. Among those, high-sensitivity testing for C-reactive
protein (CRP) is one of the best validated. Several prospective studies support a strong
link between levels of CRP and future risk of coronary events. CRP adds considerable value
to the total and HDL cholesterol measurement in the prediction of cardiovascular risk. Other
distal indicators of inflammation such as serum-amyloid polypeptide A (SAA) likewise predict
coronary risk. These distal markers reflect the consequences of elevated proinflammatory
cytokines like interleukin-6 (IL-6). GH is known to have important immunomodulatory effects.
We therefore hypothesized that the effects of GH on the process of atherosclerosis might be
mediated through the cytokine-inflammatory pathway. We have recently investigated the
effects of physiologic GH replacement in cardiovascular risk markers in men with GHD. In
this study we found that CRP and IL-6 levels decreased in GH treated men compared to
controls despite no significant change in serum lipid levels. We also recently have
investigated levels of inflammatory markers in women with hypopituitarism compared with
healthy controls. We found that women with hypopituitarism have increased levels of IL-6 and
CRP suggesting that chronic inflammation may be involved in the pathogenesis of
atherosclerosis in this population. It will be critical to determine whether physiologic GH
replacement has beneficial effects in women, and whether these effects are influenced by
estrogen.
We will investigate the effect of long-term physiologic GH administration on IL-6, CRP, SAA
as well as other classic cardiovascular risk factors in women with GHD in a randomized,
placebo-controlled study. In addition, we will evaluate structural/function correlates in
women by measuring arterial wall distensibility and heart rate variability in parallel with
cardiovascular risk markers.
We will establish the gender-specific effects of physiologic GH replacement on
cardiovascular risk in women with GHD by investigating whether this therapy:
1. has gender-specific effects on cardiovascular risk markers
2. has gender-specific effects on lipid profiles
3. alters heart rate variability and arterial distensibility in parallel with changes in
cardiovascular risk markers
4. has different effects depending upon gonadal status
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02243852 -
Effects of Growth Hormone (GH) Deficiency and Growth Hormone Replacement on Serum Fibroblast Growth Factor 21 (FGF21)
|
N/A | |
Completed |
NCT01440686 -
Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT00990340 -
Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method
|
Phase 4 | |
Completed |
NCT00235599 -
The IGFBP-3 Stimulation Test: A New Tool for the Diagnosis of Growth Hormone Deficiency in Children.
|
N/A | |
Completed |
NCT00149708 -
Consequence of Lifetime Isolated Growth Hormone Deficiency
|
N/A | |
Completed |
NCT00459940 -
The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients
|
N/A | |
Completed |
NCT01157793 -
A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood
|
Phase 4 | |
Completed |
NCT00004365 -
Study of Pituitary Size and Function in Familial Dwarfism of Sindh
|
N/A | |
Recruiting |
NCT00227253 -
Chromosome 18 Clinical Research Center
|
||
Recruiting |
NCT04121780 -
Growth Hormone Replacement Therapy for Retried Professional Football Players
|
Phase 2 | |
Completed |
NCT02934399 -
Dynamic Hormone Diagnostics in Endocrine Disease
|
||
Completed |
NCT01090778 -
Diurnal Variation of Exogenous Peptides (GH Puls/Jurgita I)
|
Phase 2 | |
Completed |
NCT01062529 -
Peripheral Metabolic Effects of Somatostatin
|
N/A | |
Completed |
NCT00965484 -
Genotropin Study Assessing Use of Injection Pen
|
Phase 3 | |
Completed |
NCT00616278 -
National Cooperative Growth Study in CKD
|
N/A | |
Completed |
NCT02693522 -
Evaluation of Efficacy and Safety of Recombinant Somatroipn in Patients With Growth Hormone Deficiency
|
Phase 3 | |
Recruiting |
NCT02908958 -
Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency
|
Phase 4 | |
Terminated |
NCT01243892 -
A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device
|
N/A | |
Withdrawn |
NCT00638287 -
Inter-Assay Growth Hormone and IGF-I Variability
|
N/A | |
Completed |
NCT00957671 -
Anterior Pituitary Hormone Replacement in Traumatic Brain Injury
|
Phase 4 |